PR YERVOY®

(ipilimumab for injection)

Patient Alert Card

This material was developed by Bristol-Myers Squibb as part of the risk minimization plan for YERVOY. This material is not intended for promotional use.

Date of internal approval: September 2020

Local Approval Number:
731CA2000193

Bristol Myers Squibb

Important Information for Patients

Please carry this card with you at all times to inform healthcare professionals that you are receiving treatment with YERVOY alone.

IMPORTANT

- Tell your doctor of any previous medical conditions, including if you have had a stem cell transplant that uses donor stem cells (allogeneic).
- Early treatment of side effects reduces the likelihood that YERVOY treatment will need to be temporarily or permanently stopped.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- **DO NOT** try to treat these symptoms yourself.
- Signs and symptoms may be delayed and may occur weeks to months after your last YERVOY injection.

POSSIBLE SIDE EFFECTS

If you have any signs or symptoms, tell your doctor right away.

BOWEL AND STOMACH

- diarrhea (loose stools) or more bowel movements than usual
- constipation
- blood in stools, or dark, tarry, sticky stools
- stomach pain (abdominal pain) or tenderness

EYE

- blurry vision, double vision or other vision problems
- eye pain or redness

NERVES

- weakness of legs, arms or face
- numbness or tingling in hands or feet

LIVER

- yellowing of your skin or the white of your eyes (jaundice)
- dark urine, tiredness, nausea or vomiting, loss of appetite, pain on the right side of your stomach or bruise easily

SKIN

- rash on your skin, mouth blisters or peeling skin

GENERAL

- headaches or unusual tiredness or sleepiness
- changes in behaviour such as less sex drive, being irritable or forgetful
- dizziness or fainting

IMPORTANT Information for Healthcare Professionals

- This patient is treated with **YERVOY** monotherapy.
- Immune-mediated adverse reactions (imARs) may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimize potential life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific imARs.
- For more information, healthcare providers should consult the YERVOY Product Monograph: https://www.bms.com/assets/bms/ca/documents/productmonograph/YERVOY_EN_PM.pdf or call BMS Medical Information at 1-866-463-6267 (toll-free).

The healthcare professional treating you with YERVOY should complete the **'My Doctor's Contact Information'** section of this Patient Alert Card.

Reporting suspected side effects

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Online at www.healthcanada.gc.ca/medeffect
- By calling 1-866-234-2345 (toll-free)
- By completing a Patient Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free),

    or
  - Mail to:
    Canada Vigilance Program
    Health Canada
    Postal Locator 1908C
    Ottawa, ON
    K1A 0K9

Postage-paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Website at www.healthcanada.gc.ca/medeffect

Note: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance program does not provide medical advice.

My Doctor's Contact Information *(who prescribed YERVOY)*

Name of Doctor: _____

Office Phone: _____

After-Hours Phone: _____

My Contact Information

My Name and Phone: _____

Caregiver Name and Phone (in case of emergency): _____

1422221

MEMBER OF
INNOVATIVE MEDICINES CANADA

14222221